ArticleScientific reports2025
Joint surveillance and correlation analysis of antimicrobial resistance and consumption of seven targeted bacteria, 2017-2023.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multicenter Genomic Analysis of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Analysis of the Etiology and Antibiotic Resistance of Bacterial Infections in Newborns in a Chinese Tertiary Hospital: From 2019 to 2024.Infection and drug resistance · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Antimicrobial resistance has been a major global threat to public health with the emergence of multidrug-resistant bacteria. We investigated the temporal trends in antimicrobial resistance and explored the relationships between antimicrobial consumption in hospitals and hospital-acquired bacterial resistance in four sub-hospitals of a large tertiary hospital in Chongqing from 2017 to 2023. The proportion of targeted isolates ranged from 52.4% (5119/9762) to 68.3% (4231/6198). Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa resistant to piperacillin/tazobactam and cefepime increased. Additionally, Acinetobacter baumannii resistant to β-lactam combination agents and carbapenems also increased. The same trends were found in oxacillin-resistant Staphylococcus aureus and linezolid-resistant Enterococcus faecium and linezolid-resistant Enterococcus faecalis. The isolation rates of hospital-acquired carbapenem-resistant Escherichia coli, carbapenem-resistant Klebsiella pneumoniae, carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii exhibited a positive correlation with the consumption of β-lactam combination agents and quinolones. The isolation rates of hospital-acquired methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium were positively correlated with the consumption of third-generation cephalosporins excluding combinations with β-lactamase inhibitors. The isolation rate of hospital-acquired vancomycin-resistant Enterococcus faecalis was positively correlated with the consumption of cephamycins. Antimicrobial consumption in hospitals was positively correlated with the isolation rates of targeted hospital-acquired multidrug-resistant bacteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.